Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

Monday, 10 October 2016 07:31

CLINUVEL Confirms Date of Annual General Meeting

Tuesday, 20 September 2016 01:25

Chair's Letter

Tuesday, 16 August 2016 01:05

Clinuvel Newsletter - August 2016

Wednesday, 10 August 2016 02:42

Form 603 - August 10, 2016 (ACN 108 768 896)

Thursday, 04 August 2016 08:56

Appendix 3Y

Wednesday, 03 August 2016 09:07

Appendix 3B

Clinuvel prepares New Drug Application (NDA) for the treatment of erythropoietic protoporphyria (EPP) Executive summary: FDA requirement for combination therapy model replicating clinical studies protocol in vitiligo fulfilled Safety of the combination therapy confirms observations in clinical trials CUV102 and CUV103 Clinuvel will request a guidance meeting with the FDA to discuss the upcoming vitiligo trial in North America Safety data add to the New Drug Application package to be submitted to the FDA for erythropoietic protoporphyria (EPP) Global experts agree on the lack of current satisfactory treatment in vitiligo Clinuvel Pharmaceuticals [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX:…
Friday, 29 July 2016 05:15

Appendix 4C - Q4 FY16

Quick Links